Summary
- Profile Type
- Technology offer
- POD Reference
- TOFR20240528010
- Term of Validity
- 28 May 2024 - 28 May 2025
- Company's Country
- France
- Type of partnership
- Research and development cooperation agreementInvestment agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
-
A French company is devoted to the innovative modification of betalactam nuclei to prepare novel hybrids as inhibitors of bacterial carbapenamases. Its plateform allows an easy conjugation of betalactam nuclei to strategically chosen molecules (simple and complex) to prepare innovative and high-quality drugs focused on unmet needs for saving lives.
Research and development cooperation agreements are sought with companies and with public research organisations. - Full Description
-
The French company is based on the independent research of one of the founders: an organic chemist with several years' experience across Europe as a postdoctoral researcher. The aim is to find an alternative way to fight antimicrobial resistance, which in 2019 caused 5 million deaths.
World Health Organisation estimated that antimicrobial resistance will be the first global cause of deaths with an economic impact of 1,5 trillion-dollar loss in 2050.
The company was founded in 2021 and has benefited from a tailor-made development program. In 2022, it received an award and the chemical platform has been growing ever since. In 2023 a collaboration for in vitro testing on carbapenamases and on some Gram-Negative Bacteria was launched with the national reference center for resistance in France.
At present, the chemical strategy has been extended to other nuclei rather than Penicillin and Cephalosporine, enabling new patents to be filed. They now offer the possibility to easily conjugate such nuclei to any organic molecule via click chemistry. Different libraries have been obtained and 30 molecules have been in vitro tested on 3 majors bacterial carbapenamases and on 5 Gram Negative pathogens.
Such innovative approach is an interesting strategy for restyling the betalactam nuclei for the generation of novel carbapenamases inhibitors even at the nanomolar scale. The molecules have shown to target different types of carbapenamases and in particular, the more active one is a metallo betalactamase inhibitor. It is important to note that metallo betalactamases represent a worldwide current unmet need.
The French company is currently looking for:
- Collaboration project with small and medium sized enterprises (SMEs) for a synergic strategy for new drug discovery. Start-ups and SMEs focusing on the synthesis of small and big molecules such as peptides, carbohydrates and macrocycle molecules are sought.
- Collaboration with start-up developing Artificial Intelligence methods for in silico study. The goal would be to better elucidate the action mechanism of the novel drugs. AI will be of absolute importance also in the prediction of new structures to implement and potentiate the activity of the new hybrids.
- Cooperation with private and public organizations to take part in a consortium dedicated to the treatment of infectious diseases.
- Partnership with big pharmaceutical industries to sponsor its project.
The French company is also interested in participating in European and American collaborative funding projects. - Advantages and Innovations
-
Betalactam scaffolds have a recognized untouchable position (the carboxylic acidi) which can not be modified under penalty of loss of activity.
The French company's strategy is based on the modification of such position to create novel reactive intermediates which undergo to click chemistry reaction ( chemicals snap together quickly and efficiently) for the preparation nfiinite libraries of novel hybrides.
Some of them have been proven to be inhibitors of major Carbapenamases invioleved in antimicrobiam resistance even at the nanomoal scale.
• First Advantage: breaking innovation for restyling betalactam scaffold. The French company is pioneering such strategy (3 patents)
• Second advantage: few chemical steps (2 to 4) to obtain inhibitors against multiple synthatic steps needed for those on the market. Under NDA the company can disclose its findings
• Third Advantage: conjugation of their intermediates with any small or very big molecules (molecules, peptides to antibodies)
• Fourth Advantage: new intellectual properties can be done.
• Fifth Advantage: “environmentally friendly” chemical strategy
• Sixth Advantage: more to discover.
At present the French company's platform is focusing on the need to prepare novel chemical strategy for the generation of inhibitors for the bacterial carbapenamases responsible of the antimicrobial resistance - Stage of Development
- Lab tested
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
Partner Sought
- Expected Role of a Partner
-
The French company is currently looking for Starups, SMEs, pharmaceutical industries and public research organisations.
- Collaboration project with small and medium sized enterprises (SMEs) for a synergic strategy for new drug discovery. Start-ups and SMEs focusing on the synthesis of small and big molecules such as peptides, carbohydrates and macrocycle molecules are sought.
- Collaboration with start-up developing Artificial Intelligence methods for in silico study. The goal would be to better elucidate the action mechanism of the novel drugs. AI will be of absolute importance also in the prediction of new structures to implement and potentiate the activity of the new hybrids.
- Cooperation with private and public organizations to take part in a consortium dedicated to the treatment of infectious diseases.
- Partnership with big pharmaceutical industries to sponsor its project,
The French company is also interested in participating in European and American collaborative funding projects. - Type and Size of Partner
- Big companyR&D InstitutionSME 11-49SME 50 - 249SME <=10University
- Type of partnership
- Research and development cooperation agreementInvestment agreement
Call details
- Coordinator required
-
Yes
Dissemination
- Technology keywords
- 03004007 - Pharmaceutics
- Market keywords
- 05007002 - Pharmaceuticals/fine chemicals05003001 - Therapeutic services
- Sector Groups Involved
- Health
- Targeted countries
- All countries